Science
At Welmedis, we have the goal of significantly improving the treatment of cancer through the development of selective and targeted anti-cancer drugs. To achieve this goal, we use our exclusive access to the RGCC transcriptomic database to analyze cancer cell profiles and identify patient population-specific therapeutic targets. Based on insights from this data, we initiate our search for targeted cancer therapies.
Many of the newly discovered therapeutic targets have no known inhibitors or available structural data. At Welmedis, we use computational chemistry tools and modern medicinal chemistry methods to overcome this challenge and generate leads for drug discovery.
Our approach at Welmedis
Our chemical development program is run from state-of-the-art laboratories in Switzerland. Our laboratories are equipped with modern synthesis equipment, including high-throughput automated synthesis and purification systems. These capabilities accelerate the hit validation and lead optimization phases, shortening our pre-clinical development.
